Adeno-associated virus vector integration junctions - PubMed (original) (raw)
Adeno-associated virus vector integration junctions
E A Rutledge et al. J Virol. 1997 Nov.
Abstract
Vectors derived from adeno-associated virus (AAV) have the potential to stably transduce mammalian cells by integrating into host chromosomes. Despite active research on the use of AAV vectors for gene therapy, the structure of integrated vector proviruses has not previously been analyzed at the DNA sequence level. Studies on the integration of wild-type AAV have identified a common site-specific integration locus on human chromosome 19; however, most AAV vectors do not appear to integrate at this locus. To improve our understanding of AAV vector integration, we analyzed the DNA sequences of several integrated vector proviruses. HeLa cells were transduced with an AAV shuttle vector, and integrated proviruses containing flanking human DNA were recovered as bacterial plasmids for further analysis. We found that AAV vectors integrated as single-copy proviruses at random chromosomal locations and that the flanking HeLa DNA at integration sites was not homologous to AAV or the site-specific integration locus of wild-type AAV. Recombination junctions were scattered throughout the vector terminal repeats with no apparent site specificity. None of the integrated vectors were fully intact. Vector proviruses with nearly intact terminal repeats were excised and amplified after infection with wild-type AAV and adenovirus. Our results suggest that AAV vectors integrate by nonhomologous recombination after partial degradation of entering vector genomes. These findings have important implications for the mechanism of AAV vector integration and the use of these vectors in human gene therapy.
Similar articles
- Cellular recombination pathways and viral terminal repeat hairpin structures are sufficient for adeno-associated virus integration in vivo and in vitro.
Yang CC, Xiao X, Zhu X, Ansardi DC, Epstein ND, Frey MR, Matera AG, Samulski RJ. Yang CC, et al. J Virol. 1997 Dec;71(12):9231-47. doi: 10.1128/JVI.71.12.9231-9247.1997. J Virol. 1997. PMID: 9371582 Free PMC article. - Herpes simplex virus type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19.
Heister T, Heid I, Ackermann M, Fraefel C. Heister T, et al. J Virol. 2002 Jul;76(14):7163-73. doi: 10.1128/jvi.76.14.7163-7173.2002. J Virol. 2002. PMID: 12072516 Free PMC article. - Adeno-associated virus general transduction vectors: analysis of proviral structures.
McLaughlin SK, Collis P, Hermonat PL, Muzyczka N. McLaughlin SK, et al. J Virol. 1988 Jun;62(6):1963-73. doi: 10.1128/JVI.62.6.1963-1973.1988. J Virol. 1988. PMID: 2835501 Free PMC article. - Site-specific integration by adeno-associated virus.
Linden RM, Ward P, Giraud C, Winocour E, Berns KI. Linden RM, et al. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11288-94. doi: 10.1073/pnas.93.21.11288. Proc Natl Acad Sci U S A. 1996. PMID: 8876128 Free PMC article. Review. - Integration of adeno-associated virus (AAV) and recombinant AAV vectors.
McCarty DM, Young SM Jr, Samulski RJ. McCarty DM, et al. Annu Rev Genet. 2004;38:819-45. doi: 10.1146/annurev.genet.37.110801.143717. Annu Rev Genet. 2004. PMID: 15568995 Review.
Cited by
- Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1.
Torella L, Klermund J, Bilbao-Arribas M, Tamayo I, Andrieux G, Chmielewski KO, Vales A, Olagüe C, Moreno-Luqui D, Raimondi I, Abad A, Torrens-Baile J, Salido E, Huarte M, Hernaez M, Boerries M, Cathomen T, Zabaleta N, Gonzalez-Aseguinolaza G. Torella L, et al. EMBO Mol Med. 2024 Jan;16(1):112-131. doi: 10.1038/s44321-023-00008-8. Epub 2024 Jan 5. EMBO Mol Med. 2024. PMID: 38182795 Free PMC article. - Topoisomerase Inhibitors Increase Episomal DNA Expression by Inducing the Integration of Episomal DNA in Hepatic Cells.
Gómez-Moreno A, San Sebastian E, Moya J, Gomollón-Zueco P, Isola S, Vales Á, González-Aseguinolaza G, Unzu C, Garaigorta U. Gómez-Moreno A, et al. Pharmaceutics. 2023 Oct 13;15(10):2459. doi: 10.3390/pharmaceutics15102459. Pharmaceutics. 2023. PMID: 37896219 Free PMC article. - Gene therapy for liver diseases - progress and challenges.
Zabaleta N, Unzu C, Weber ND, Gonzalez-Aseguinolaza G. Zabaleta N, et al. Nat Rev Gastroenterol Hepatol. 2023 May;20(5):288-305. doi: 10.1038/s41575-022-00729-0. Epub 2023 Jan 16. Nat Rev Gastroenterol Hepatol. 2023. PMID: 36646909 Review. - Evaluating the state of the science for adeno-associated virus integration: An integrated perspective.
Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, McCarty DM, Montini E, Ndu A, Yuan J; American Society of Gene and Cell Therapy (ASGCT) Working Group on AAV Integration. Sabatino DE, et al. Mol Ther. 2022 Aug 3;30(8):2646-2663. doi: 10.1016/j.ymthe.2022.06.004. Epub 2022 Jun 10. Mol Ther. 2022. PMID: 35690906 Free PMC article. Review. - The Role of Recombinant AAV in Precise Genome Editing.
Bijlani S, Pang KM, Sivanandam V, Singh A, Chatterjee S. Bijlani S, et al. Front Genome Ed. 2022 Jan 13;3:799722. doi: 10.3389/fgeed.2021.799722. eCollection 2021. Front Genome Ed. 2022. PMID: 35098210 Free PMC article. Review.
References
- J Mol Biol. 1967 Jun 14;26(2):365-9 - PubMed
- Proc Natl Acad Sci U S A. 1968 Jul;60(3):992-9 - PubMed
- Virology. 1975 Dec;68(2):556-60 - PubMed
- Fed Proc. 1976 Jul;35(9):2037-43 - PubMed
- J Gen Virol. 1977 Jul;36(1):59-74 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources